EMA Withdrawn: Neupopeg (pegfilgrastim) — Dompé Biotec S.p.A.

View source ↗

Summary

EMA withdrawn Neupopeg (pegfilgrastim) by Dompé Biotec S.p.A. indicating the product is no longer active in the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Neupopeg (pegfilgrastim)

Snippet

Status: Withdrawn. Therapeutic area: Cancer. MAH: Dompé Biotec S.p.A.. Decision date: 18/04/2008